Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance

Sima P. Porten, Jared M Whitson, Janet E. Cowan, Matthew R. Cooperberg, Katsuto Shinohara, Nannette Perez, Kirsten L. Greene, Maxwell V. Meng, Peter R. Carroll

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

Purpose: Active surveillance is now considered a viable treatment option for men with low-risk prostate cancer. However, little is known regarding changes in Gleason grade on serial biopsies over an extended period of time. Patients and Methods: Men diagnosed with prostate cancer between 1998 and 2009 who elected active surveillance as initial treatment, with 6 or more months of follow-up and a minimum of six cores at biopsy, were included in analysis. Upgrading and downgrading were defined as an increase or decrease in primary or secondary Gleason score. Means and frequency tables were used to describe patient characteristics, and treatment-free survival rates were determined by life-table product limit estimates. Results: Three hundred seventy-seven men met inclusion criteria. Mean age at diagnosis was 61.9 years. Fifty-three percent of men had prostate-specific antigen of 6 ng/mL or less, and 94% had Gleason score of 6 or less. A majority of men were cT1 (62%), had less than 33% of biopsy cores involved (80%), and were low risk (77%) at diagnosis. Median number of cores taken at diagnostic biopsy was 13, mean time to follow-up was 18.5 months, and 29% of men had three or more repeat biopsies. Overall, 34% (129 men) were found to have an increase in Gleason grade. The majority of men who experienced an upgrade (81%) did so by their second repeat biopsy. Conclusion: A proportion of men experience an upgrade in Gleason score while undergoing active surveillance. Men who experience early upgrading likely represent initial sampling error, whereas later upgrading may reflect tumor dedifferentiation.

Original languageEnglish (US)
Pages (from-to)2795-2800
Number of pages6
JournalJournal of Clinical Oncology
Volume29
Issue number20
DOIs
StatePublished - Jul 10 2011
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Biopsy
Neoplasm Grading
Life Tables
Selection Bias
Prostate-Specific Antigen
Therapeutics
Survival Rate
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Porten, S. P., Whitson, J. M., Cowan, J. E., Cooperberg, M. R., Shinohara, K., Perez, N., ... Carroll, P. R. (2011). Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. Journal of Clinical Oncology, 29(20), 2795-2800. https://doi.org/10.1200/JCO.2010.33.0134

Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. / Porten, Sima P.; Whitson, Jared M; Cowan, Janet E.; Cooperberg, Matthew R.; Shinohara, Katsuto; Perez, Nannette; Greene, Kirsten L.; Meng, Maxwell V.; Carroll, Peter R.

In: Journal of Clinical Oncology, Vol. 29, No. 20, 10.07.2011, p. 2795-2800.

Research output: Contribution to journalArticle

Porten, SP, Whitson, JM, Cowan, JE, Cooperberg, MR, Shinohara, K, Perez, N, Greene, KL, Meng, MV & Carroll, PR 2011, 'Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance', Journal of Clinical Oncology, vol. 29, no. 20, pp. 2795-2800. https://doi.org/10.1200/JCO.2010.33.0134
Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N et al. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. Journal of Clinical Oncology. 2011 Jul 10;29(20):2795-2800. https://doi.org/10.1200/JCO.2010.33.0134
Porten, Sima P. ; Whitson, Jared M ; Cowan, Janet E. ; Cooperberg, Matthew R. ; Shinohara, Katsuto ; Perez, Nannette ; Greene, Kirsten L. ; Meng, Maxwell V. ; Carroll, Peter R. / Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. In: Journal of Clinical Oncology. 2011 ; Vol. 29, No. 20. pp. 2795-2800.
@article{b428bbf1f0eb475bbdfeda8392de6a85,
title = "Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance",
abstract = "Purpose: Active surveillance is now considered a viable treatment option for men with low-risk prostate cancer. However, little is known regarding changes in Gleason grade on serial biopsies over an extended period of time. Patients and Methods: Men diagnosed with prostate cancer between 1998 and 2009 who elected active surveillance as initial treatment, with 6 or more months of follow-up and a minimum of six cores at biopsy, were included in analysis. Upgrading and downgrading were defined as an increase or decrease in primary or secondary Gleason score. Means and frequency tables were used to describe patient characteristics, and treatment-free survival rates were determined by life-table product limit estimates. Results: Three hundred seventy-seven men met inclusion criteria. Mean age at diagnosis was 61.9 years. Fifty-three percent of men had prostate-specific antigen of 6 ng/mL or less, and 94{\%} had Gleason score of 6 or less. A majority of men were cT1 (62{\%}), had less than 33{\%} of biopsy cores involved (80{\%}), and were low risk (77{\%}) at diagnosis. Median number of cores taken at diagnostic biopsy was 13, mean time to follow-up was 18.5 months, and 29{\%} of men had three or more repeat biopsies. Overall, 34{\%} (129 men) were found to have an increase in Gleason grade. The majority of men who experienced an upgrade (81{\%}) did so by their second repeat biopsy. Conclusion: A proportion of men experience an upgrade in Gleason score while undergoing active surveillance. Men who experience early upgrading likely represent initial sampling error, whereas later upgrading may reflect tumor dedifferentiation.",
author = "Porten, {Sima P.} and Whitson, {Jared M} and Cowan, {Janet E.} and Cooperberg, {Matthew R.} and Katsuto Shinohara and Nannette Perez and Greene, {Kirsten L.} and Meng, {Maxwell V.} and Carroll, {Peter R.}",
year = "2011",
month = "7",
day = "10",
doi = "10.1200/JCO.2010.33.0134",
language = "English (US)",
volume = "29",
pages = "2795--2800",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "20",

}

TY - JOUR

T1 - Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance

AU - Porten, Sima P.

AU - Whitson, Jared M

AU - Cowan, Janet E.

AU - Cooperberg, Matthew R.

AU - Shinohara, Katsuto

AU - Perez, Nannette

AU - Greene, Kirsten L.

AU - Meng, Maxwell V.

AU - Carroll, Peter R.

PY - 2011/7/10

Y1 - 2011/7/10

N2 - Purpose: Active surveillance is now considered a viable treatment option for men with low-risk prostate cancer. However, little is known regarding changes in Gleason grade on serial biopsies over an extended period of time. Patients and Methods: Men diagnosed with prostate cancer between 1998 and 2009 who elected active surveillance as initial treatment, with 6 or more months of follow-up and a minimum of six cores at biopsy, were included in analysis. Upgrading and downgrading were defined as an increase or decrease in primary or secondary Gleason score. Means and frequency tables were used to describe patient characteristics, and treatment-free survival rates were determined by life-table product limit estimates. Results: Three hundred seventy-seven men met inclusion criteria. Mean age at diagnosis was 61.9 years. Fifty-three percent of men had prostate-specific antigen of 6 ng/mL or less, and 94% had Gleason score of 6 or less. A majority of men were cT1 (62%), had less than 33% of biopsy cores involved (80%), and were low risk (77%) at diagnosis. Median number of cores taken at diagnostic biopsy was 13, mean time to follow-up was 18.5 months, and 29% of men had three or more repeat biopsies. Overall, 34% (129 men) were found to have an increase in Gleason grade. The majority of men who experienced an upgrade (81%) did so by their second repeat biopsy. Conclusion: A proportion of men experience an upgrade in Gleason score while undergoing active surveillance. Men who experience early upgrading likely represent initial sampling error, whereas later upgrading may reflect tumor dedifferentiation.

AB - Purpose: Active surveillance is now considered a viable treatment option for men with low-risk prostate cancer. However, little is known regarding changes in Gleason grade on serial biopsies over an extended period of time. Patients and Methods: Men diagnosed with prostate cancer between 1998 and 2009 who elected active surveillance as initial treatment, with 6 or more months of follow-up and a minimum of six cores at biopsy, were included in analysis. Upgrading and downgrading were defined as an increase or decrease in primary or secondary Gleason score. Means and frequency tables were used to describe patient characteristics, and treatment-free survival rates were determined by life-table product limit estimates. Results: Three hundred seventy-seven men met inclusion criteria. Mean age at diagnosis was 61.9 years. Fifty-three percent of men had prostate-specific antigen of 6 ng/mL or less, and 94% had Gleason score of 6 or less. A majority of men were cT1 (62%), had less than 33% of biopsy cores involved (80%), and were low risk (77%) at diagnosis. Median number of cores taken at diagnostic biopsy was 13, mean time to follow-up was 18.5 months, and 29% of men had three or more repeat biopsies. Overall, 34% (129 men) were found to have an increase in Gleason grade. The majority of men who experienced an upgrade (81%) did so by their second repeat biopsy. Conclusion: A proportion of men experience an upgrade in Gleason score while undergoing active surveillance. Men who experience early upgrading likely represent initial sampling error, whereas later upgrading may reflect tumor dedifferentiation.

UR - http://www.scopus.com/inward/record.url?scp=79960240491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960240491&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.33.0134

DO - 10.1200/JCO.2010.33.0134

M3 - Article

C2 - 21632511

AN - SCOPUS:79960240491

VL - 29

SP - 2795

EP - 2800

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 20

ER -